Chemotherapy as a part of each treatment fraction in a twice-a-day hyperfractionated schedule: A new chemoradiotherapy approach for advanced head and neck cancer
✍ Scribed by Jose L. de Serdio; Alfonso Villar; Jose C. Martinez; Maria D. Perez; Jose J. Martin; Claudio Fuentes; Jose Gil-Curbelo; Ruth Hernandez; Marcos Suñer; Manuel Espiñeira; Juan J. Artazkoz; Juan A. Saavedra
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 89 KB
- Volume
- 20
- Category
- Article
- ISSN
- 1043-3074
No coin nor oath required. For personal study only.
✦ Synopsis
Background. Using chemotherapy as a part of each treatment fraction remains unexplored. This study integrates the concomitant administration of carboplatin with hyperfractionated irradiation by optimizing chemopotentiation through carboplatin administration with each irradiation fraction.
Methods. From February 1993 to August 1996, 52 patients with advanced head and neck cancer were treated on a twice-aday chemoradiotherapy schedule. Each fraction consisted of 115 cGy preceded by 5 mg/m 2 of carboplatin. Treatment was given 5 days a week up to total doses of 350 mg/m 2 of carboplatin + 8050 cGy in 7 weeks.
Results. All (100%) of patients tolerated the treatment (83% as scheduled). Acute and late toxicities were moderate. Rates of 96% complete response (CR) and 4% partial response (PR) were achieved. At 52 months, local control and cause-specific survival rates are 72% and 59%, respectively. Nodal control rate is 95%.
Conclusion. These results show potential for improvement upon hyperfractionated radiotherapy alone and compare favorably with those of most reported trials.